Assessing the Effects of Fanapt® on Social Cognition in Schizophrenia

PHASE4TerminatedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

February 28, 2014

Study Completion Date

October 31, 2014

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG

Iloperidone

Patients in this study will be treated with Fanapt® (iloperidone). They will begin a standardized up-titration starting with a dose of 2 mg daily. Dose increases will continue until the subject has achieved clinical stability, has achieved the maximum dose of 24 mg/day, or until 8 weeks have elapsed. Once clinical stability has been achieved, the patient will continue into the treatment phase. If clinical stability is not achieved after 8 weeks, the patient will be excluded from the study.

Trial Locations (1)

60611

Northwestern University, Chicago

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Northwestern University

OTHER